 Epoxide Hydrolases
"Epoxide Hydrolases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a glycol or aromatic diol, respectively.
| Descriptor ID |
D004851
|
| MeSH Number(s) |
D08.811.277.340
|
| Concept/Terms |
Epoxide Hydrolases- Epoxide Hydrolases
- Hydrolases, Epoxide
- Epoxide Hydratases
- Hydratases, Epoxide
- Epoxide Hydrases
- Hydrases, Epoxide
9,10-Epoxypalmitic Acid Hydrase- 9,10-Epoxypalmitic Acid Hydrase
- 9,10 Epoxypalmitic Acid Hydrase
- Acid Hydrase, 9,10-Epoxypalmitic
- Hydrase, 9,10-Epoxypalmitic Acid
|
Below are MeSH descriptors whose meaning is more general than "Epoxide Hydrolases".
Below are MeSH descriptors whose meaning is more specific than "Epoxide Hydrolases".
This graph shows the total number of publications written about "Epoxide Hydrolases" by people in UAMS Profiles by year, and whether "Epoxide Hydrolases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 | | 2020 | 1 | 1 | 2 | | 2019 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2014 | 4 | 1 | 5 | | 2013 | 3 | 1 | 4 | | 2012 | 4 | 0 | 4 | | 2011 | 5 | 1 | 6 | | 2010 | 1 | 0 | 1 | | 2009 | 4 | 0 | 4 | | 2008 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2005 | 3 | 1 | 4 | | 2004 | 2 | 0 | 2 | | 2002 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Epoxide Hydrolases" by people in Profiles over the past ten years.
-
Khan MAH, Nolan B, Stavniichuk A, Merk D, Imig JD. Dual soluble epoxide hydrolase inhibitor - farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis. Front Immunol. 2023; 14:1269261.
-
Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochem Pharmacol. 2022 01; 195:114866.
-
Obeng S, Hiranita T, Le?n F, McMahon LR, McCurdy CR. Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. J Med Chem. 2021 05 27; 64(10):6523-6548.
-
Grapov D, Fiehn O, Campbell C, Chandler CJ, Burnett DJ, Souza EC, Casazza GA, Keim NL, Hunter GR, Fernandez JR, Garvey WT, Hoppel CL, Harper ME, Newman JW, Adams SH. Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women. Physiol Rep. 2020 09; 8(17):e14547.
-
Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Bl?cher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 10; 150:106472.
-
Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.
-
Cert?kov? Ch?bov? V, Kujal P, Vanourkov? Z, ?karoupkov? P, Sadowski J, Kompanowska-Jezierska E, Tesar V, Hammock B, Imig J, Maxov? H, Cervenka L, Vaneckov? I. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney Blood Press Res. 2019; 44(6):1493-1505.
-
Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol. 2019 08; 166:212-221.
-
Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203.
-
Hye Khan MA, Kolb L, Skibba M, Hartmann M, Bl?cher R, Proschak E, Imig JD. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 10; 61(10):2235-2246.
-
Cert?kov? Ch?bov? V, Kujal P, ?karoupkov? P, Varnourkov? Z, Vackov? ?, Huskov? Z, Kikerlov? S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesar V, Cervenka L. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):329-349.
-
Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765.
-
Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat. 2016 09; 125:40-7.
-
Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|